EBGI Category: Liver
-
ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockers
American College of Gastroenterology / EBGI Articles / Liver / ICYMI: Can we prevent hepatic decompensation? Most likely, with nonselective beta blockersIn Case You Missed It Can We Prevent Hepatic Decompensation? Most Likely, With Nonselective Beta Blockers Sonali Paul, MD, MS…
-
Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone
American College of Gastroenterology / EBGI Articles / Liver / Direct-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) EveryoneDirect-Acting Antiviral Therapy for Hepatitis C Virus Decreases All-Cause Mortality and Decompensated Cirrhosis: Treat (Virtually) Everyone Philip Schoenfeld, MD, MSEd,…
-
ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM Trial
American College of Gastroenterology / EBGI Articles / Liver / ICYMI: Is Terlipressin for the Treatment of Hepato-Renal Syndrome Ready for Primetime: Results of the CONFIRM TrialThis summary reviews Wong F, Pappas SC, Curry MP, et al. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome. N Engl J Med. 2021 Mar 4;384(9):818-828.
-
Prophylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy
American College of Gastroenterology / EBGI Articles / Liver / Prophylactic Rifaximin Decreases Post-TIPS Hepatic EncephalopathyProphylactic Rifaximin Decreases Post-TIPS Hepatic Encephalopathy Philip Schoenfeld, MD, MSEd, MScEpi, FACG Chief Emeritus-Gastroenterology Section, John D. Dingell VA Medical…
-
When to Use Prophylactic Antibiotics for Management of Acute-on-Chronic Liver Failure?
American College of Gastroenterology / EBGI Articles / Liver / When to Use Prophylactic Antibiotics for Management of Acute-on-Chronic Liver Failure?When to Use Prophylactic Antibiotics for Management of Acute-on-Chronic Liver Failure? Sonali Paul, MD, MS Assistant Professor of Medicine, Division…
-
Hepatic Decompensation Rate Is 0.05 per 100 person-years in NAFLD with Stage F0-F2 Fibrosis, but Rises to 1 per 100 person-years with Stage F3
American College of Gastroenterology / EBGI Articles / Liver / Hepatic Decompensation Rate Is 0.05 per 100 person-years in NAFLD with Stage F0-F2 Fibrosis, but Rises to 1 per 100 person-years with Stage F3Hepatic Decompensation Rate Is 0.05 per 100 person-years in NAFLD with Stage F0-F2 Fibrosis, but Rises to 1 per 100…
-
Inching Closer to a NASH Cure: Daily Semaglutide Achieves Resolution of NASH but Not Fibrosis after 72 Weeks
American College of Gastroenterology / EBGI Articles / Liver / Inching Closer to a NASH Cure: Daily Semaglutide Achieves Resolution of NASH but Not Fibrosis after 72 WeeksInching Closer to a NASH Cure: Daily Semaglutide Achieves Resolution of NASH but Not Fibrosis after 72 Weeks Sonali Paul,…